Skip to main navigation menu Skip to main content Skip to site footer

Vol. 13 No. 4 (2026)
International Multidisciplinary Journal for Research & Development

Articles

NEUROLOGICAL DISORDERS ACCOMPANIED BY COGNITIVE IMPAIRMENTS AND THE RELEVANCE OF OPTIMIZING THEIR TREATMENT

Published 2026-04-02

  • Sokhib Rashidov Zamon o'g'li,Davronbek A'zamov Salim o'g'li,Zukhriddin Oʻrishboev Alisher oʻgʻli

Sokhib Rashidov Zamon o'g'li,Davronbek A'zamov Salim o'g'li,Zukhriddin Oʻrishboev Alisher oʻgʻli
Department of the pharmacology of the Tashkent state medical university

Abstract

Cognitive impairments are often linked to Parkinson's disease (PD), a neurodegenerative ailment. These may result directly from the underlying illness or may be brought on by outside variables in vulnerable people who have Parkinson's disease or other risk factors. The cognitive disorders include delirium, cognitive side effects of PD treatment, cognitive non-motor fluctuations, PD-associated psychosis, and PD-associated cognitive impairment (PD-CI). Since delirium frequently results from an underlying illness that may be severe and call for specialized care, an accurate diagnosis is essential. A general deterioration in memory and other cognitive abilities that is severe enough to impair a person's capacity to carry out daily tasks is referred to as dementia. It is characterized by a steady and progressive decline in cognitive function. Memory loss and a partial or substantial lack of understanding of their deficiencies are common in affected patients. The assessment and treatment of dementia are reviewed in this activity, which also emphasizes the interprofessional team's involvement in providing care for patients with this illness. It also discusses pathogenesis, risk factors, and difficulties in identifying and treating this range of cognitive illnesses. However, it is believed that delirium and Parkinson's disease (PD) have comparable clinical symptoms due to shared molecular pathways. Furthermore, delirium and PD-CI interact in both directions, leading to frequent concurrent processes that make identification even more challenging. Currently, there is no trustworthy biomarker for delirium, and clinical criteria are the main basis for diagnosis. However, there is no specific validation for PD in the screening techniques that have been validated for identifying delirium in the general population. Our review identifies current gaps in the research and discusses the difficulties in diagnosing these cognitive impairments.

Keywords

Alzheimer's disease, Psychiatry for the elderly, Mental Illness, The study of neuropsychology, Parkinson's illness, Mental Illness, Parkinson's Disease Non-Motor Symptoms, Treatment Strategies.

PDF

References

  1. Bonnechère B, Amin N, van Duijn C. What Are the Key Gut Microbiota Involved in Neurological Diseases? A Systematic Review. Int J Mol Sci. 2022 Nov 8;23(22):13665. doi: 10.3390/ijms232213665.
  2. Benito-León J, Papaliagkas V. Cognitive Impairment in Neurological Diseases. Int J Mol Sci. 2024 Apr 18;25(8):4435. doi: 10.3390/ijms25084435.
  3. Aarsland, D., Batzu, L., Halliday, G.M. et al. Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers 7, 47 (2021). https://doi.org/10.1038/s41572-021-00280-3
  4. Aripov A.N., Aripov O.A., Akhundjanova L.L., Nabiev A.U., Nabieva D.A., & Khamroev T.T. (2022). Study the effect of yantacin on some indicators of cellular renewal and on the level of protein expression on rat hepatocytes in chronic heliotrine liver damage. International Journal of Medical Sciences And Clinical Research, 2(05), 06–13. https://doi.org/10.37547/ijmscr/Volume02Issue05-02.
  5. Chojnacki, C.; Konrad, P.; Błońska, A.; Medrek-Socha, M.; Przybylowska-Sygut, K.; Chojnacki, J.; Poplawski, T. Altered Tryptophan Metabolism on the Kynurenine Pathway in Depressive Patients with Small Intestinal Bacterial Overgrowth. Nutrients 2022, 14, 3217.
  6. Aripov A. N, Akhunzhanova L. L, Nabiev A. U, Aripov A. O, Khamroev T. T.. Antifibrotic Efficacy of a New Phytocomposition of Essential Phospholipids with Glycyrrhizic Acid, Ecdysterone, Lycopene and Proanthacyanidin in Experimental Severe Chronic Hepatitis Compared with Phosphogliv. Biomed Pharmacol J 2023;16(3).Pages : 1815-1825. DOI : https://dx.doi.org/10.13005/bpj/2761
  7. Socała K., Doboszewska U., Szopa A., Serefko A., Włodarczyk M., Zielińska A., Poleszak E., Fichna J., Wlaź P. The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders. Pharmacol. Res. 2021;172:105840. doi: 10.1016/j.phrs.2021.105840.
  8. Aripov A.N, Akhunjanova L.L, Khamroev T.T, Aripov Abdumalik Nigmatovich, Akhunjanova Lola Lazizovna, & Khamroev Tolmas Tolibovich. (2022). Differential Analysis of Chronic Toxic Hepatitis Caused by The Introduction of Heliotrin Solution in Various Ways. Texas Journal of Medical Science, 4, 58–62. Retrieved from https://zienjournals.com/index.php/tjms/article/view/670
  9. Rashidov S.Z., Rakhimboev S.D., Sanoev Z.I., Abdinazarov I.T., Khamroev T.T., Ismailova D.S., & Elmuradov B.J.. (2022). Study of psychoactive activity potassium salt 5-(o-aminophenyl)-1,3,4- oxadiazole-2-thion (D-361). International Journal of Medical Sciences And Clinical Research, 2(09), 1–5. https://doi.org/10.37547/ijmscr/Volume02Issue09-01
  10. Góralczyk-Bińkowska, A.; Szmajda-Krygier, D.; Kozłowska, E. The Microbiota–Gut–Brain Axis in Psychiatric Disorders. Int. J. Mol. Sci. 2022, 23, 11245.
  11. Heiss C.N., Olofsson L.E. The Role of the Gut Microbiota in Development, Function and Disorders of the Central Nervous System and the Enteric Nervous System. J. Neuroendocrinol. 2019;31:e12684. doi: 10.1111/jne.12684.
  12. Арипов А.Н., Арипов О.А., Ахунджанова Л.Л., Набиев А.Ў., Нишанбаев С.З., Набиева Д.А., Ҳамроев Т.Т. Тажриба шароитида сафорофлавонолозиднинг гепатотроп фаоллигини ўрганиш. Oriental Journal of Medicine and Pharmacology, 2(02), 55–64. https://doi.org/10.37547/supsci-ojmp-02-02-07
  13. Angst D., Gessier F., Janser P., Vulpetti A., Wälchli R., Beerli C., et al. Discovery of LOU064 (Remibrutinib), a potent and highly selective covalent inhibitor of Bruton’s Tyrosine Kinase. J. Med. Chem. 2020;63(10):5102–5118. doi: 10.1021/acs.jmedchem.9b01916.
  14. Zakhidova L.T., Saidkhodjaeva D.M., Sanoev Z.I., Tukhtasheva V.F., Rakhmanova H.A.., Hamroyev T.T. Toxicological Characteristics Of N-Deacetyllappaconitine Under Chronic Administration In White Rats. The American Journal of Applied Sciences, 3(03), 34-41. https://doi.org/10.37547/tajas/Volume03Issue03-06
  15. Guerra E., Garcia-Sanchez Y., Jornet-Gibert M., Nuñez J., Balaguer-Castro M., Madden K. Clinical practice guidelines: The good, the bad, and the ugly. Injury. 2022;54((Suppl. S3)):S26–S29. doi: 10.1016/j.injury.2022.01.047.
  16. Khamroev T.T., Sanoev Z.I., Rakhimboev S.D., Abdinazarov I.T., Rashidov S.Z. Effect of antiarrhythmic substance N – dezacetyllapoconitin on the central nervous system. ISJ Theoretical &Applied Science, 07 (99), 153-157. http://soi.org/1.1/TAS-07-99-31 Doi:https://dx.doi.org/10.15863
  17. Asahina Y., Wurtz N.R., Arakawa K., Carson N., Fujii K., Fukuchi K., et al. Discovery of BMS-986235/LAR-1219: a potent formyl peptide receptor 2 (FPR2) selective agonist for the prevention of heart failure. J. Med. Chem. 2020;63(17):9003–9019. doi: 10.1021/acs.jmedchem.9b02101.
  18. Sanoev Z.I., Abdinazarov I.T., Rakhimboev S.D., Rashidov S.Z., Hamroyev T.T. Study Of The General Pharmacological Properties Of A New Antiarrhythmic N-Deacetyllappaconitine With Oral Administration. The American Journal of Medical Sciences and Pharmaceutical Research, 3(03), 60-64. https://doi.org/10.37547/TAJMSPR/Volume03Issue03-08
  19. Patton E.E., Zon L.I., Langenau D.M. Zebrafish disease models in drug discovery: From preclinical modelling to clinical trials. Nat. Rev. Drug Discov. 2021;20:611–628. doi: 10.1038/s41573-021-00210-8.
  20. Sanoev Z. I, Ismailova D. S, Rakhimboev S. D. O, Khamroev T, T, Elmuradov B. Z, Abdinazarov I. T, Rashidov S. Z. O. Synthesis and Research Anticonvulsant Activity of Annulated Triazolo-Thiadiazine Derivative in Laboratory Animals. Biomed Pharmacol J 2023;16(4). DOI : https://dx.doi.org/10.13005/bpj/2820
  21. Stokes, J.M.; Yang, K.; Swanson, K.; Jin, W.; Cubillos-Ruiz, A.; Donghia, N.M.; MacNair, C.R.; French, S.; Carfrae, L.A.; Bloom-Ackermann, Z. A deep learning approach to antibiotic discovery. Cell 2020, 180, 688–702.e613.
  22. Sanoev, Z.I., Djaxangirov, F.N., Sadikov, A.Z., Sagdullaev, S.S. Hamroyev T.T. Antiarrhythmic activity of N-deacetyllappaconitine when administered orally. Annals of the Romanian Society for Cell Biology,2021,25(2), 2339–2346. https://doi.org/10.37547/tajas/Volume03Issue03-06
  23. Thafar, M.A.; Alshahrani, M.; Albaradei, S.; Gojobori, T.; Essack, M.; Gao, X. Affinity2Vec: Drug-target binding affinity prediction through representation learning, graph mining, and machine learning. Sci. Rep. 2022, 12, 4751.
  24. Sokhib Rashidov Zamon oʻgʻli, Muslimakhon Kamolova Mirzokhidjon qizi, Ikhvoliddin Mirzaev Komiljon o‘g‘li, Nodira Pardaeva Botir qizi, Sevara Rakhmatullaeva Shukhrat qizi/. (2025). The importance of cardiotonic drugs in medical practice, the range of applications and the advantages of their use. International Journal of Cognitive Neuroscience and Psychology, 3(5), 95–100. Retrieved from https://medicaljournals.eu/index.php/IJCNP/article/view/1856
  25. Frileux, S.; Boltri, M.; Doré, J.; Leboyer, M.; Roux, P. Cognition and Gut Microbiota in Schizophrenia Spectrum and Mood Disorders: A Systematic Review. Neurosci. Biobehav. Rev. 2024, 162, 105722.
  26. Sanoev Zafar Isomiddinovich, Rashidov Sokhib Zamon ugli, Raximboev Sukhrob Davlatyor ugli, Abdinazarov Ibrokhim Tuychievich, Khamroev Tolmas Tolibovich, Ismailova Dilnoza Safaralievna, & Elmuradov Burkhon Juraevich. (2022). Research of Anticonvulsant Activity of Compound 5- (P-Aminophenyl) - 1,3,4-Oxadiazole-2-Thion. Texas Journal of Medical Science, 13, 17–21. Retrieved from https://zienjournals.com/index.php/tjms/article/view/2434
  27. Yu. R. Mirzaev, T. T. Khamroev, E. M. Ruzimov, B. N. Khandamov, & Sh. M. Adizov. (2022). Evaluation of the Effect on the Nervous System of Substances with an Alkaloid Structure Having Antitumor Activity. Journal Healthcare Treatment Development(JHTD) ISSN : 2799-1148, 2(06), 6–10. Retrieved from http://journal.hmjournals.com/index.php/JHTD/article/view/1577
  28. Kong Y.K., Song K.-S., Jung M.E., Kang M., Kim H.J., Kim M.J. Discovery of GCC5694A: A potent and selective sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes. Bioorg. Med. Chem. Lett. 2022;56 doi: 10.1016/j.bmcl.2021.128466.
  29. Aripov A.N., Aripov O.A., Akhunjanova L.L., Nabiev A.O., Nabieva D.A., & Khamroev T.T. (2022). Study the antifibrous efficacy of plant proanthocyanidin in rats with chronic heliotrine liver damage. Frontline Medical Sciences and Pharmaceutical Journal, 2(05), 16–25. https://doi.org/10.37547/medical-fmspj-02-05-03.
  30. Sokhib Rashidov Zamon oʻgʻli, Nilufar Ergasheva Agʼzamjon qizi, Elyor Zokirboyev Anvarjon o‘gli, Umidjon Akramov Abdusamad o‘g‘li, & Aziza Egamberdieva Farkhod qizi. (2025). Drugs That Increase the Tone of the Human Body and Pharmacological Characteristics of Immunodeficiency Agents. American Journal of Biomedicine and Pharmacy, 2(5), 300–306. Retrieved from https://biojournals.us/index.php/AJBP/article/view/1065
  31. Günther J., Hillig R.C., Zimmermann K., Kaulfuss S., Lemos C., Nguyen D., et al. BAY-069, a Novel (Trifluoromethyl) pyrimidinedione-Based BCAT1/2 Inhibitor and Chemical Probe. J. Med. Chem. 2022;65(21):14366–14390. doi: 10.1021/acs.jmedchem.2c00441.
  32. Sokhib Rashidov Zamon oʻgʻli, Murodjon Nabiev Mahammadkarim o‘g‘li, Mo'tabar Yoqubjonova Khusanboy qizi, Shakhzodakhon Bekmurodova Poʻlatjon qizi, & Jumanazar To‘ychiev Saidqul o‘g‘li. (2025). Comparative Analysis of Drugs Used for Anemia and Drugs Storing Iron. Research Journal of Trauma and Disability Studies, 4(5), 190–195. Retrieved from https://journals.academiczone.net/index.php/rjtds/article/view/5141
  33. Rosa J.G.S., Lima C., Lopes-Ferreira M. Zebrafish larvae behavior models as a tool for drug screenings and pre-clinical trials: A review. Int. J. Mol. Sci. 2022;23:6647. doi: 10.3390/ijms23126647.
  34. Sokhib Rashidov Zamon oʻgʻli, Shakhzoda Abduraimova Abdusattor qizi, Nigora Yusufjonova Mirrakhim qizi, Diyora Turdibekova Erkinjon qizi, & Makhsuma Dovutkho’jayeva Maqsudjonovna. (2025). Classification, Indications for Use, Range of Applications and Disadvantages of Medicines against Nematodes and Leishmania. Research Journal of Trauma and Disability Studies, 4(5), 196–201. Retrieved from https://journals.academiczone.net/index.php/rjtds/article/view/5142
  35. Sokhib Rashidov Zamon oʻgʻli, Nigora Yusufjonova Mirrakhim qizi, Diyora Turdibekova Erkinjon qizi, Makhsuma Dovutkho’jaeva Maqsudjonovna, Shakhzoda Abduraimova Abdusattor qizi, Analysis of the effect of medicines used in medical practice for various diseases on the fetus , european journal of modern medicine and practice: Vol. 5 No. 5 (2025) 342-347.
  36. Cockerill G.S., Angell R.M., Bedernjak A., Chuckowree I., Fraser I., Gascon-Simorte J., et al. Discovery of sisunatovir (RV521), an inhibitor of respiratory syncytial virus fusion. J. Med. Chem. 2021;64(7):3658–3676. doi: 10.1021/acs.jmedchem.0c01882.
  37. Sokhib Rashidov Zamon oʻgʻli, Elyor Zokirboev Anvarjon ògli, Umidjon Akramov Abdusamad o‘g‘li, Aziza Egamberdiyeva Farkhod qizi, Munisa Qoʻshbekova Roʻzimbek qizi. (2025). Analysis of general and specific pharmacological properties of fat-soluble vitamins. International Journal of Cognitive Neuroscience and Psychology, 3(5), 101–106. Retrieved from https://medicaljournals.eu/index.php/IJCNP/article/view/1857
  38. Daniels, C., Rodríguez-Antigüedad, J., Jentschke, E. et al. Cognitive disorders in advanced Parkinson’s disease: challenges in the diagnosis of delirium. Neurol. Res. Pract. 6, 14 (2024). https://doi.org/10.1186/s42466-024-00309-4
  39. Emmady PD, Schoo C, Tadi P. Major Neurocognitive Disorder (Dementia) [Updated 2022 Nov 19]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557444/
  40. Vakhnina NV. Current therapy for cognitive impairments. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2011;3(4):63-69. (In Russ.) https://doi.org/10.14412/2074-2711-2011-349

Downloads

Download data is not yet available.